ASH 2022 | Modakafusp alfa: a promising agent in the myeloma treatment landscape
Mohamad Mohty
• 10 Dec 2022
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into the promise of modakafusp alfa, a novel innate immunity engager, for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). Prof. Mohty explains that this agent has shown to induce responses in patients who are resistant to anti-CD38 monoclonal antibodies with minimal toxicity, and further comments on the potential of combining modakafusp alfa with other agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
